AAPK-25

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.

AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis. AAPK-25 targets Aurora A, Aurora B, and Aurora C with Kd values ??ranging from 23-289 nM, and PLK1, PLK2, and PLK3 with Kd values ??ranging from 55-456 nM. AAPK-25 has antitumor activity.(In Vitro):AAPK-25 inhibited HCT-116, Calu6, A549, and MCF-7 cells growth (IC50s: 0.4, 5.3, 11.6, and 2.3 μM). AAPK-25 dose-dependently induced apoptosis in HCT-116 cell line.(In Vivo):In the BALB/c nude mice tumor xenograft model, AAPK-25 enhanced the survival rate.

——

Apoptosis

Apoptosis

——

——

——

2247919-28-2

442.3

C21H13Cl2N3O2S

>98% (HPLC)

——

Clc1ccc(cc1Cl)C(=O)Nc1ccc2cc(ccc2c1)C(=O)Nc1nccs1

——

(-20℃)

With Ice Pack

≥ 2 years